Damaged capsules have been identified in batches of Lenalidomide Mylan, with powder visible inside the blister pocket. For all strengths and pack sizes, healthcare professionals should carefully inspect blisters and avoid dispensing packs with any damaged capsule. Such packs must be returned for replacement; undamaged packs may be dispensed with strict handling precautions.

Women who are pregnant or may become pregnant should not handle the product at any time. If damage is noted, do not open the capsule- return for replacement. Always use disposable gloves when touching capsules, dispose of gloves safely, and wash hands thoroughly after handling. If powder contacts skin, wash immediately with soap and water. Patients and caregivers should be advised on these handling measures and asked to return any defective units they spot.

The manufacturer, Viatris, has begun recalling affected batches and is also providing this guidance in case a recall would cause shortages in some areas. Healthcare professionals are encouraged to report any suspected adverse drug reactions through the national reporting system, including batch or lot numbers.

Lenalidomide is an important drug for treating several blood cancers, so these strict measures help protect both patients and healthcare workers from accidental exposure or reduced medicine efficacy.

Learn more: Lenalidomide Mylan (lenalidomide): potential for damaged capsules and precautionary handling measures